As I type this, I’m enjoying a five hour layover in Las Vegas by trying to get this post up instead of trying out those slot machines. I am en-route to Vienna, Austria. The main photo in this post is of my final joint smoked outside of the Vancouver International Airport.
As I lose access to legal recreational Cannabis by heading outside of the country, I remember why I need to travel globally and push productive dialogue. I’m spoiled in Canada, and immensely proud of that fact. I hope to help bring the positive change around Cannabis outside of the Canadian border as the world watches us during this paradigm shift in international drug policy.
I will be attending parts of the “Reconvened Sixty-first Session of the Commission on Narcotic Drugs” December 5th to 7th. I will also be attending the International Cannabis Policy Conference December 7th to 9th.
Informed High is a bronze sponsor of this event. This event is organized by FAAAT think & do tank – an NGO registered in Paris, France. For those who happen to be at this event in Vienna, come check out my booth for some Informed High swag and conversations about cannabis.
I am absolutely thrilled and nervous to be a part of such a historic moment in time. The results of the first-ever scientific review of Cannabis and THC will be revealed.
For those wondering how Cannabis got onto the Schedule I. and even strictor subset of Schedule I. that is Schedule IV. The answer has little to do with the science of Cannabis and more with international policy, fear, racism, capitalism, and ideology. While repeated attempts to call for a scientific review have been denied due to waiting for more evidence. They didn’t wait for evidence in the first place, but at least they are looking at it now.
The World Health Organization’s Expert Committe on Drug Dependence “consists of an independent group of experts in the field of drugs and medicines.” who has the job of assessing “the health risks and benefits of the use of psychoactive substances according to a set of fixed criteria. These criteria are:
- Evidence of dependence potential of the substance
- Actual abuse and/or evidence of likelihood of abuse
- Therapeutic applications of the substance
Depending on the outcome of this assessment, suggestions may be made to change the international drug status of Cannabis and THC. This committee already completed its critical review of CBD specifically. Here are some important bits from the summary:
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential.
CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with one pure CBD product (Epidiolex®) with completed Phase III trials and under current review for approval in the U.S. There is also preliminary evidence that CBD may be a useful treatment for a number of other medical conditions.
There is unsanctioned medical use of CBD based products with oils, supplements, gums, and high concentration extracts available online for the treatment of many ailments.
CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.
Several countries have modified their national controls to accommodate CBD as a medicinal product.
To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD.”
I will be updating this blog as best as I can. You can check out live updates on my instgram – @Informed.High
PS: since I had like five hours here, I did end up playing some slots. And it’s my lucky day, as I walk away with $40 USD. Here’s to a nice meal bought with my winnings 🙂